4.70
price down icon0.84%   -0.04
after-market 시간 외 거래: 4.75 0.05 +1.06%
loading

Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스

pulisher
Jul 28, 2025

How many analysts rate Vanda Pharmaceuticals Inc. as a “Buy”Overwhelming profit margins - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Should I hold or sell Vanda Pharmaceuticals Inc. stock in 2025Free Trading Psychology Coaching - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Vanda Pharmaceuticals Inc. generate profit in a changing economyBuild a diversified portfolio for stability - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What institutional investors are buying Vanda Pharmaceuticals Inc. stockAchieve consistent profits with disciplined trading - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is Vanda Pharmaceuticals Inc. a growth stock or a value stockExceptional trading performance - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

Is Vanda Pharmaceuticals Inc. a good long term investmentRapid wealth accumulation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

When is the best time to buy Vanda Pharmaceuticals Inc. stockPowerful profit generation - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 - Barchart.com

Jul 24, 2025
pulisher
Jul 23, 2025

Vanda Pharmaceuticals Inc. Stock Analysis and ForecastSkyrocketing investment returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Vanda Pharmaceuticals Inc. stockAccelerated capital growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Vanda Pharmaceuticals Inc. stock priceMassive profits - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - beatles.ru

Jul 19, 2025
pulisher
Jul 17, 2025

Vanda Pharmaceuticals’ Study on Trichostatin A: A Potential Game-Changer in Hematologic Malignancies - TipRanks

Jul 17, 2025
pulisher
Jul 09, 2025

US FDA Will Not Pull Teva And MSN Hetlioz ANDAs, Rejects Vanda Citizen Petitions - insights.citeline.com

Jul 09, 2025
pulisher
Jun 30, 2025

Vanda Pharmaceuticals Inc.(NasdaqGM: VNDA) added to Russell 2000 Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 17, 2025

Insider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharm - GuruFocus

Jun 17, 2025
pulisher
Jun 13, 2025

DC Circ. Urged To Reject Approval For Braille-Free Drug Label - Law360

Jun 13, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - StreetInsider

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial E - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals (VNDA) Initiates First Human Trial for Ant - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda's Breakthrough: First-Ever Personalized Treatment Trial Launches for Ultra-Rare CMT2S Disease - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S | VNDA Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 09, 2025

Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4) - Quantisnow

Jun 09, 2025
pulisher
Jun 05, 2025

Vanda Approves Key Proposals at Annual Meeting - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow

Jun 05, 2025
pulisher
Jun 05, 2025

CLASS ACTION UPDATE for SPB, VNDA and ARA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Jun 05, 2025
$23.09
price down icon 1.32%
$37.06
price up icon 1.06%
$101.75
price down icon 2.12%
$27.45
price down icon 4.26%
$112.79
price down icon 2.19%
biotechnology ONC
$294.51
price up icon 1.04%
자본화:     |  볼륨(24시간):